Advanced glycation end products (AGEs) are heterogeneous group of molecules formed from nonenzymatic reaction of reducing sugars with amino group of proteins, lipids, and nucleic acid. Interaction of AGEs with its cell-bound receptor (RAGE) results in generation of oxygen radicals, nuclear factor kappa-β, proinflammatory cytokines and cell adhesion molecules, and is involved in the pathophysiology of cardiovascular diseases (CVD). Circulating soluble forms of RAGE (sRAGE) and endo-secretory RAGE (esRAGE) compete with RAGE for ligand binding and function as a decoy. This paper describes the endogenous and exogenous (high dietary AGEs, and cooking food under high dry heat, elevated pH, and longer period) sources of AGEs. AGERAGE- mediated CVD includes atherosclerosis, coronary artery disease, carotid artery disease, hypertension, peripheral vascular diseases, heart failure, cardiomyopathy, and microangiopathy. The therapeutic interventions with reduction in AGEs and RAGE, and elevation in sRAGE has been reported for the treatment of AGE-RAGEmediated CVD. Reduction in levels of AGEs can be achieved by reduction in consumption of food containing low amount of AGEs, cooking food at low temperature, moist heat, and shorter duration. AGE formation can be reduced with drugs, vitamins and stoppage of cigarette smoking. Statins, telmisartan, and curcumin have been used for suppression of RAGE. Statins, ACE-inhibitors, Rosiglitazone and vitamin D have been used to increase levels of sRAGE. Finally exogenous administration of sRAGE can be helpful in amelioration of CVD. In conclusion, AGE-RAGE-mediated CVD could be attenuated with reduction in consumption of AGEs, suppression of RAGE and elevation of sRAGE.
Keywords: Advanced glycation end products, receptor for AGE, soluble receptors for AGE, cardiovascular disease, aminoguanidine, statins, dietary AGE, vitamins.
Platelet Glycoprotein IIb / IIIa Inhibition and its Clinical Use
Current Medicinal Chemistry - Cardiovascular & Hematological Agents An Update on Drug Interactions with the Herbal Medicine Ginkgo biloba
Current Drug Metabolism The Inflammation Paradigm and Coronary Artery Disease: What Celsus, Virchow and Gene Knock Outs Have Taught Us
Cardiovascular & Hematological Disorders-Drug Targets The Potential Protective Effects of Phenolic Compounds against Low-density Lipoprotein Oxidation
Current Pharmaceutical Design Humoral Immunity in Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets Development of Tissue Engineered Vascular Grafts
Current Pharmaceutical Biotechnology Interactions Between the Sympathetic Nervous System and Angiotensin System in Renovascular Hypertension
Current Hypertension Reviews Current Management of Peripheral Vascular Disease: Where is the Evidence?
Cardiovascular & Hematological Agents in Medicinal Chemistry Macrophages: Promising Targets for the Treatment of Atherosclerosis
Current Vascular Pharmacology Peripheral Vascular Disease: The Role of MR- Angiography
Current Medical Imaging Relevance of Endothelial-Haemostatic Dysfunction in Cigarette Smoking
Current Medicinal Chemistry G-protein Dependent Platelet Signaling - Perspectives for Therapy
Current Drug Targets Development of Scaffolds for Vascular Tissue Engineering: Biomaterial Mediated Neovascularization
Current Stem Cell Research & Therapy Circulating Aminopeptidase Activities in Men and Women with Essential Hypertension
Current Medicinal Chemistry Enhancing Cardiovascular Dynamics by Inhibition of Thrombospondin- 1/CD47 Signaling
Current Drug Targets Smoking and Atherosclerosis: Mechanisms of Disease and New Therapeutic Approaches
Current Medicinal Chemistry Diabetic Heart and the Cardiovascular Surgeon
Cardiovascular & Hematological Disorders-Drug Targets The Role of Angiotensin Type 1 Receptor in Inflammation and Endothelial Dysfunction
Recent Patents on Cardiovascular Drug Discovery (Discontinued) Anti-Platelet Therapy and Aspirin Resistance – Clinically and Chemically Relevant?
Current Medicinal Chemistry Adult Stem Cells and the Clinical Arena: Are we Able to Widely Use this Therapy in Patients with Chronic Limbs Arteriopathy and Ischemic Ulcers without Possibility of Revascularization?
Cardiovascular & Hematological Agents in Medicinal Chemistry